Small molecules inhibiting the kinase activity of the ABL protein were developed and exhibited anti-leukemic activity, leading to dramatic therapeutic effects in CML [81]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.